Our R&D team has identified and further modified the coronaviral (e.g. COVID-19) and HCV RdRp-binding sites, of which the related patents have been filed for not only securing IP protection but also supporting the development of samRNA technologies. Two major samRNA technologies have been well established; one is Replicase/RdRp Cycling Reaction (RCR) and the other is samRNA medicine/vaccine.
Our Technology
RCR
Replicase/RdRp Cycling Reaction
RCR is a novel in-vitro RNA amplification technology optimized for industrial grade production of RNA/mRNA-based medicines as well as vaccines. Using recombinant viral replicase/RdRp enzymes, samRNA can be directly amplified from itself without the hassle of any DNA contamination. Most importantly, the amplified samRNA are all in full-length conformation because both of its 5’- and 3’-end RdRp-binding sites are required for RCR activities, resulting in no or very limited RNA/mRNA degradation.
SamRNA
Self-amplifying mRNA
SamRNA is one of the most advanced and advantageous RNA/mRNA medicine design in the world. By changing the coding RNA/mRNA sequence between the 5’- and 3’-end RdRp-binding sites of samRNA, we can design ad manufacture different RNA/mRNA medicines and/or vaccines useful for developing a variety of treatments against many human diseases, such as viral infections, cancers, diabetes, Alzheimer’s disease, and many more.
